Humuline 30/70 Cartridge

Humuline 30/70 Cartridge is a prescription insulin that contains human insulin in a premixed 30/70 formulation (30 % rapid‑acting regular insulin and 70 % intermediate‑acting NPH insulin) supplied in a cartridge for insulin pens. It is marketed in the European Union and used under medical supervision for diabetes management. The cartridge holds a fixed dose volume, enabling accurate subcutaneous delivery for patients requiring both basal and prandial coverage.

Humuline 30/70 Cartridge is indicated for the treatment of diabetes mellitus where a combination of rapid and intermediate insulin action is appropriate.

- Adults with type 1 diabetes who need a premixed insulin regimen. - Adults with type 2 diabetes inadequately controlled on oral agents alone. - Situations where a single daily injection can provide both basal and mealtime insulin coverage. - Patients transitioning from separate regular and NPH insulin injections to a simplified delivery system. - Use in combination with diet, exercise, and other glucose‑lowering therapies as directed by a healthcare professional.

Adverse reactions to Humuline 30/70 may vary in frequency and severity, and they can affect different organ systems.

Common: - Mild hypoglycemia, especially if meals are delayed or carbohydrate intake is insufficient. - Injection site reactions such as redness, swelling, or itching. - Lipodystrophy, presenting as localized thickening or loss of subcutaneous fat. - Transient weight gain associated with improved glycemic control. - Nausea or mild gastrointestinal discomfort. - Headache or dizziness, often related to fluctuating glucose levels. - Localized bruising or hematoma at the injection site.

Serious: - Severe hypoglycemia with neuroglycopenic symptoms (confusion, seizures, loss of consciousness). - Allergic reactions ranging from urticaria to anaphylaxis. - Persistent edema or heart failure exacerbation in susceptible individuals. - Acute pancreatitis presenting with abdominal pain and elevated enzymes.

When prescribing or using Humuline 30/70, healthcare professionals should consider several precautionary measures to ensure safe and effective therapy.

- Assess renal and hepatic function before initiation and periodically thereafter. - Adjust dose in patients with variable meal patterns or increased physical activity. - Monitor for signs of hypoglycemia, especially in the elderly or those with impaired awareness. - Use caution in pregnant or breastfeeding women; benefits must outweigh potential risks. - Avoid using the cartridge after the expiration date or if the solution appears discolored or contains particles. - Educate patients on proper injection technique and rotation of sites to prevent lipodystrophy.

Humuline 30/70 may interact with other medications, altering its glucose‑lowering effect or increasing the risk of adverse events.

Avoid: - Concurrent use of other rapid‑acting insulins or high‑dose insulin secretagogues that may precipitate severe hypoglycemia. - Beta‑blockers that can mask hypoglycemia symptoms. - Corticosteroids, which can raise blood glucose and necessitate insulin dose adjustments.

Use with caution: - Oral antidiabetic agents such as sulfonylureas or meglitinides, requiring close monitoring of blood glucose. - Thiazide diuretics, which may increase insulin resistance. - ACE inhibitors or ARBs, as they can affect renal function and insulin clearance. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may impair renal function and affect insulin metabolism. - Alcohol consumption, which can cause unpredictable glucose fluctuations and potentiate hypoglycemia.